India Immunology Drugs Market to Grow with a CAGR of 7.08% through 2030
Increasing prevalence of immunological disorders and
innovative & new product launches is expected to drive the India Immunology
Drugs Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “India Immunology
Drugs Market-Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030”, the India Immunology Drugs Market stood at USD 2.65 Billion in 2024 and is
anticipated to grow with a CAGR of 7.08% in the forecast period, 2026-2030. The
India Immunology Drugs Market is primarily driven by several key factors. The
increasing prevalence of immunological disorders, such as rheumatoid arthritis
and multiple sclerosis, is one major driving force.
India's robust pharmaceutical industry
and its capacity for high-volume generic drug production contribute
significantly to market growth. Advances in biologic drug development and a
growing understanding of immunological diseases have also allowed for more
targeted and effective therapies, further propelling market expansion. Increased healthcare expenditures and a growing awareness about immunological
disorders among the public are also contributing to the growth of this market.
India, with its vast population and burgeoning middle
class, presents a significant and lucrative market for immunology drugs. These
drugs, specifically designed to modulate the immune system, play a pivotal role
in the treatment of various diseases, including autoimmune disorders,
infectious diseases, and cancers. Over the past decade, the Indian immunology
drugs market has witnessed exponential growth, fueled by expanding healthcare
infrastructure and improved access to medical services.
Both established pharmaceutical giants and emerging
local companies are making notable inroads into this promising market. Several
factors contribute to its growth, including the increasing awareness about
autoimmune diseases, rising healthcare expenditure, and the advent of
biosimilars. The prevalence of immunology-related diseases, such
as rheumatoid arthritis, psoriasis, and Crohn’s disease, has been on the rise,
further driving the demand for these drugs. However, challenges persist in the
form of the high cost of immunology drugs and the complexity associated with
drug development. The pricing of these medications often renders them
unaffordable for the average Indian consumer, limiting access. The
development of new drugs requires substantial resources and time, making it a
high-risk endeavor for market players.
Nonetheless, the advent of biosimilars, which are
essentially more affordable versions of biologic drugs, has the potential to
disrupt the market and increase accessibility. Indian pharmaceutical companies,
leveraging their expertise in generic drugs, are at the forefront of biosimilar
development, contributing to the market's dynamics.
The Indian government's focus on improving healthcare
infrastructure and making healthcare more affordable presents a unique
opportunity for the immunology drugs market. Policies such as Ayushman Bharat,
the world's largest government-funded healthcare program, are expected to drive
the demand for these drugs. The COVID-19 pandemic has further highlighted the
critical role of immunology in disease management and prevention, amplifying
the spotlight on immunology drugs. This has resulted in increased awareness and
demand, further bolstering the market's growth prospects.
While the Indian immunology drugs market faces certain
obstacles, the overall outlook remains positive. With continued investment in
healthcare and the surge in the development of biosimilars, the market is
poised for substantial growth in the coming years. Despite the challenges, the
potential of the Indian immunology drugs market is immense, and its strategic
importance on the global stage is indisputable. The continuous exploration of
innovative solutions and collaborations will be instrumental in unlocking its
full potential.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Immunology Drugs Market”
The India Immunology Drugs Market is segmented into drug
class, indication, end user, regional distribution, and company.
Based on end user, hospitals, being the primary
healthcare facilities, play a crucial role in the administration and usage of
immunology drugs. With their extensive reach and capacity to cater to a large
number of patients, hospitals experience a higher demand and consumption of
immunology medications. This is mainly due to the fact that hospitals are
equipped with specialized medical professionals and advanced infrastructure,
making them ideal for the treatment and management of various immunological
conditions. In addition to providing comprehensive medical care, hospitals
often collaborate with research institutes and pharmaceutical companies to stay
updated with the latest advancements in immunology. This ensures that patients
receive the most effective and innovative therapies available.
Hospitals serve as important hubs for
clinical trials and research studies related to immunological disorders. These
collaborations contribute to the development of new drugs and therapies,
further expanding the treatment options available to patients. The close
association between hospitals and research institutes also fosters a culture of
continuous learning and knowledge exchange among healthcare professionals. Hospitals
& clinics hold a significant position in the Indian immunology drugs
market. Their extensive reach, specialized expertise, and collaborations with
research institutes and pharmaceutical companies make them pivotal in
delivering effective and innovative immunology treatments to patients.
Based on region, North India is notably dominating the
Indian Immunology Drugs Market due to several factors. The region's dense
population, combined with various environmental and lifestyle factors, leads to
a greater prevalence of immunological disorders, thereby increasing the demand
for immunology drugs. This includes factors such as pollution, stress, and
dietary patterns that contribute to the higher incidence of these disorders. There
is a high level of healthcare infrastructure and medical facilities in this
region, ensuring better access to these drugs. The presence of well-established
hospitals, research centers, and pharmaceutical companies further supports the
availability and distribution of immunology drugs.
North India is home to a significant
number of renowned medical professionals, including immunologists and
specialists in related fields. This concentration of expertise plays a crucial
role in diagnosing and treating immunological disorders effectively, thereby
driving the demand for immunology drugs. The presence of affluent states in
North India, with higher per capita incomes, also contributes to the higher
consumption of immunology drugs. People in these states have the means to
afford the cost of these treatments, ensuring wider accessibility and
utilization of immunology drugs. The combination of a dense population, robust
healthcare infrastructure, concentration of medical professionals, and the
presence of affluent states makes North India a dominant force in the Indian
Immunology Drugs Market, with increasing demand and consumption of these
essential medications.
Major companies operating in India Immunology Drugs
Market are:
- Panacea Biotec Ltd.
- Bristol-Myers Squibb India Pvt Ltd.
- Wockhardt Ltd.
- Pfizer Ltd.
- Sanofi India Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- Abbott India Ltd.
- Genetech Pvt Ltd.
- Novartis India Ltd.
- Allergan India Pvt Ltd.
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The India Immunology Drugs Market is anticipated to
witness significant growth over the upcoming years. This is attributed to the
rising incidence of immunological disorders, such as rheumatoid arthritis and
multiple sclerosis, and the expanding aging population who are more susceptible
to such diseases. Increased investment in healthcare
infrastructure, the presence of a robust pipeline of immunology drugs, and
heightened awareness about immunological disorders are factors that are
expected to drive the market.,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“India Immunology
Drugs Market By Drug Class (Monoclonal Antibodies (mAb), Antibody Drug
Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication,
Others), By Indication (Arthritis, Plaque Psoriasis, Spondylitis, Inflammatory
Bowel Disease, Transplant Rejection, Others), By End User (Hospitals & Clinics,
Cancer Research Institute, Others), By Region, Competition, Forecast &
Opportunities, 2020-2030F”, has evaluated
the future growth potential of India Immunology Drugs Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Immunology Drugs Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com